IVD Products

HapOnco^® CorePanel Common Solid Tumor Genomic Profiling Kit

HapOnco^® CorePanel Common Solid Tumor Genomic Profiling Kit is designed to detect 136 genes highly associated with tumor development, progression, treatment, and prognosis in formalin-fixed paraffin-embedded (FFPE) samples from solid tumor patients.

HapOnco^® StarPanel Solid Tumor Genomic Profiling Kit

HapOnco^® StarPanel Solid Tumor Genomic Profiling Kit is used to detect mutations in 1326 genes that are highly related to tumor occurrence, development, and treatment prognosis in solid tumors, using panel capture, NGS sequencing, and bioinformatics analysis of formalin-fixed paraffin-embedded (FFPE) tumor tissue samples.

HapOnco^® WESPlus Whole Exome Sequencing Genomic Profiling Kit

HapOnco^® WESPlus Whole Exome Sequencing Genomic Profiling Kit is based on high-throughput targeted hybrid-capture sequencing technology (Next generation sequencing , NGS). The assay performs high-quality whole-exome sequencing (WES) on genomic DNA extracted from FFPE tumor tissue samples, covering the complete exonic regions of approximately 20,000 human genes with ultra-deep sequencing depth. This test enables comprehensive detection of single-nucleotide variants (SNVs), small insertions/deletions (InDels), and copy number variations (CNVs), and additionally includes detection of clinically relevant gene fusions/rearrangements, tumor mutational burden (TMB) calculation, microsatellite instability (MSI) assessment, and analysis of hereditary cancer-related genes, providing a broad molecular basis for clinical decision-making.

HapOnco^® mClean MRD Detection Kit (Digestive Cancers)

HapOnco^® mClean MRD Detection Kit (Digestive Cancers) is based on the Tumor-naive/agnostic immobilized Panel mode for ctDNA-MRD detection. It is suitable for in vitro detection of Minimal Residual Disease (MRD) in plasma cell-free DNA samples from patients with gastrointestinal tumors such as colorectal cancer, gastric cancer, esophageal cancer and gastrointestinal stromal tumor. It is designed by a Panel dedicated to 190 gastrointestinal tumor-related genes. There were 14 targeted drug/drug resistance related genes, 15 immunoefficacy related genes, MSI detection and 9 inherited tumor related genes. This kit covers the recommended genes of WHO guidelines, Chinese expert consensus and literature reports, covering 96% of the population of digestive tract tumors, and the mutation types include base replacement (SNV), small fragment insertion deletion (Indel), fusion, and gene rearrangement.

HapEnrich^® Nucleic Acid Extraction Kit (Tissue)

The kit is used for the extraction, enrichment and purification of nucleic acids. The processed products are intended for clinical in vitro diagnostic use.

GeneBrain^TM Cancer Genomics Insight System

The system integrates a tumor NGS intelligent analysis and interpretation platform with high-performance computing and storage capabilities. It combines data demultiplexing, data analysis, report interpretation, sample management, data management, and knowledge base management into a unified solution. Equipped with patented bioinformatics software, databases, and interpretation knowledge bases, the system enables intelligent and automated processing from raw sequencing data to final reports. Designed to ensure data security, it can operate independently of public networks, specifically addressing the challenges of in-hospital clinical NGS implementation, including bioinformatics analysis, report interpretation, data management, and network security—making NGS simpler and more accessible.